Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition.
10.3346/jkms.2014.29.4.468
- Author:
Eunsoo WON
1
;
Seon Cheol PARK
;
Kyu Man HAN
;
Seung Hwan SUNG
;
Hwa Young LEE
;
Jong Woo PAIK
;
Hong Jin JEON
;
Moon Soo LEE
;
Se Hoon SHIM
;
Young Hoon KO
;
Kang Joon LEE
;
Changsu HAN
;
Byung Joo HAM
;
Joonho CHOI
;
Tae Yeon HWANG
;
Kang Seob OH
;
Sang Woo HAHN
;
Yong Chon PARK
;
Min Soo LEE
Author Information
1. Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea. leeminso@korea.ac.kr
- Publication Type:Review ; Practice Guideline
- Keywords:
Depression;
Pharmacological Treatment;
Guideline;
Korea
- MeSH:
Antidepressive Agents/*therapeutic use;
Antipsychotic Agents/therapeutic use;
Databases, Factual;
Depression/complications/diagnosis/*drug therapy;
Drug Tolerance;
Evidence-Based Practice;
Humans;
Monoamine Oxidase Inhibitors/therapeutic use;
Neurotransmitter Uptake Inhibitors/therapeutic use;
Placebo Effect;
Psychotic Disorders/complications/drug therapy;
Republic of Korea;
Severity of Illness Index
- From:Journal of Korean Medical Science
2014;29(4):468-484
- CountryRepublic of Korea
- Language:English
-
Abstract:
This paper aims to introduce, summarize, and emphasize the importance of the 'Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition'. The guideline broadly covers most aspects of the pharmacological treatment of patients in Korea diagnosed with moderate to severe major depression according to the DSM-IV TR. The guideline establishment process involved determining and answering a number of key questions, searching and selecting publications, evaluating recommendations, preparing guideline drafts, undergoing external expert reviews, and obtaining approval. A guideline adaptation process was conducted for the revised edition. The guideline strongly recommends pharmacological treatment considered appropriate to the current clinical situation in Korea, and should be considered helpful when selecting the appropriate pharmacological treatment of patients diagnosed with major depressive disorder. Therefore, the wide distribution of this guideline is recommended.
